Chugai Pharmaceutical Co., Ltd. (CHGCF)

Chugai Pharmaceutical Balance Sheet

Financials in millions JPY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	497,088	540,202	458,674	222,169	267,753	212,333
Short-Term Investments	530,521	456,143	280,308	280,938	204,217	166,287
Cash & Short-Term Investments	1,027,609	996,345	738,982	503,107	471,970	378,620
Cash Growth	25.99%	34.83%	46.88%	6.60%	24.65%	13.68%
Accounts Receivable	316,747	334,256	318,892	512,538	355,081	253,342
Other Receivables	210	896	1,456	1,745	928	12
Receivables	316,957	335,152	320,348	514,283	356,009	253,354
Inventory	235,526	240,067	273,480	292,206	208,838	183,893
Prepaid Expenses	-	23,013	21,827	18,770	17,301	14,997
Other Current Assets	39,440	11,466	11,789	8,171	9,543	4,042
Total Current Assets	1,619,532	1,606,043	1,366,426	1,336,537	1,063,661	834,906
Property, Plant & Equipment	471,346	441,554	420,701	386,651	352,107	297,490
Long-Term Investments	-	73,073	61,086	56,185	44,663	31,287
Other Intangible Assets	33,292	17,868	19,860	25,141	21,974	23,880
Long-Term Deferred Tax Assets	72,019	69,835	64,474	65,244	56,287	47,934
Other Long-Term Assets	82,158	-	-	-	2	1
Total Assets	2,278,347	2,208,373	1,932,547	1,869,758	1,538,694	1,235,498
Accounts Payable	78,417	65,353	112,468	209,835	152,266	100,396
Accrued Expenses	-	49,324	44,629	37,751	34,421	31,575
Current Portion of Leases	-	6,365	6,975	6,434	6,550	6,649
Current Income Taxes Payable	71,797	142,499	71,573	121,160	108,293	83,313
Current Unearned Revenue	-	31	31	79	86	80
Other Current Liabilities	118,062	26,785	52,541	48,471	25,806	14,057
Total Current Liabilities	268,276	290,357	288,217	423,730	327,422	236,070
Long-Term Leases	-	4,532	6,480	7,675	9,490	4,635
Long-Term Deferred Tax Liabilities	5,217	5,076	5,787	7,086	7,614	9,166
Other Long-Term Liabilities	15,507	2,974	3,337	3,569	3,206	3,342
Total Liabilities	293,220	306,874	306,967	445,371	350,677	255,495
Common Stock	73,202	73,202	73,202	73,202	73,202	73,202
Additional Paid-In Capital	70,271	69,896	69,355	68,806	68,223	67,586
Retained Earnings	1,847,516	1,746,934	1,488,738	1,293,352	1,054,050	849,093
Comprehensive Income & Other	-5,862	11,467	-5,715	-10,973	-7,458	-9,878
Total Common Equity	1,985,127	1,901,499	1,625,580	1,424,387	1,188,017	980,003
Shareholders' Equity	1,985,127	1,901,499	1,625,580	1,424,387	1,188,017	980,003
Total Liabilities & Equity	2,278,347	2,208,373	1,932,547	1,869,758	1,538,694	1,235,498
Total Debt	-	10,897	13,455	14,109	16,040	11,284
Net Cash (Debt)	1,027,609	985,448	725,527	488,998	455,930	367,336
Net Cash Growth	25.99%	35.83%	48.37%	7.25%	24.12%	14.68%
Net Cash Per Share	624.42	598.82	440.92	297.20	277.12	223.29
Filing Date Shares Outstanding	1,646	1,646	1,645	1,645	1,644	1,644
Total Common Shares Outstanding	1,646	1,646	1,645	1,645	1,644	1,644
Working Capital	1,351,256	1,315,686	1,078,209	912,807	736,239	598,836
Book Value Per Share	1206.25	1155.56	988.01	865.88	722.50	596.16
Tangible Book Value	1,951,835	1,883,631	1,605,720	1,399,246	1,166,043	956,123
Tangible Book Value Per Share	1186.02	1144.70	975.94	850.59	709.13	581.63

Updated Jan 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.